Word

AVANTI POLAR LIPIDS, INC.

Status

Pending

Status Code

654

Status Date

Monday, November 7, 2022

Serial Number

88632780

Mark Type

3000

Filing Date

Thursday, September 26, 2019

Trademark Owner History

AVANTI POLAR LIPIDS, LLC - 1st New Owner Before Publication
Avanti Polar Lipids, Inc. - Original Applicant

Classifications

40 cGMP custom manufacture of active agents, additives, or excipients for others; cGMP custom manufacture of lipids for others; custom manufacturing services for others in the field of active agents, additives, or excipients in pharmaceutical preparations; custom manufacturing services for others in the field of lipids; providing information relating to lipids and related compounds for scientific and medical research purposes

5 Chemical compounds for pharmaceutical or medical use; biometallic compounds for pharmaceutical or medical use; adjuvants for medical use; immunostimulatory compounds for medical use; medical diagnostic reagents; test strips for the detection of bacterial infections for medical use; isotopes for medical use

1 Chemical compounds for scientific or research use; adjuvants for scientific or research use; chemical reagents for the delivery of lipids for scientific or research use; chemical compounds for use as standards for use with analytical techniques, namely, mass spectrometry; compounds for scientific or research use, namely, lipids, synthetic lipids, polymer modified lipids, lipids with modified head groups, lipids with modified acyl chains, bioactive lipids, fluorescent lipids, isotope labeled lipids, oxidized lipids, sphingolipids, lipid extracts from natural sources, lipids conjugated with modified gold particles; compounds for scientific or research use, namely, fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, sterol lipids, prenol lipids, lipid preparations suitable for protein crystallization, lipid preparations suitable for protein solubilization, detergents, amphiphilic detergents, and antibodies; diagnostic reagents and analytical reagents for scientific or research use; formulations comprising lipids for scientific or research use; enzymes for scientific or research use; lipids, chemical additives, and excipients for use in the manufacture of pharmaceutical preparations

42 Analytical services, namely, performing nutraceutical testing, NMR analysis, mass spectrometry analysis, infrared spectroscopy analysis, chromatography analysis, gas chromatography analysis, particle size analysis, zeta potential analysis, thin layer chromatography analysis, water content, peroxide oxidation, and phosphorous content analysis, stability testing, and analytical method development and validation; scientific research for medical purposes; analytical services, namely, performing nutraceutical testing, NMR analysis, mass spectrometry analysis, infrared spectroscopy analysis, chromatography analysis, gas chromatography analysis, particle size analysis, zeta potential analysis, thin layer chromatography analysis, water content, peroxide oxidation, and phosphorous content analysis, stability testing, and analytical method development and validation in the field of lipids, nutraceuticals, food products, pharmaceutical products, drug development and commercialization; scientific research and product development and consultation related thereto in the field of pharmaceuticals and chemicals; scientific research services for others; scientific research services for others in the field of lipids, nutraceuticals, food products, pharmaceutical products, drug development and commercialization; lipidomics services, namely, identification and quantification of lipid compounds in a sample, identification of protein-lipid interactions, and identifying the role of lipids in cellular signaling; cGMP testing services, namely method design, development, qualification and validation, lipid raw material release testing, developing standard operating procedures, quality assurance review, product testing release, and stability testing; formulation services, namely, development and production of liposome and nanoparticle formulations, scaling-up manufacturing processes, and synthesis of lipid compounds for use in formulations, in the field of pharmaceuticals, lipids, and chemicals; providing information relating to chemical characterization, analysis methods, and uses of lipids and related compounds for scientific and medical research purposes

The mark consists of the word "AVANTI" in a stylized font above the words "POLAR LIPIDS, INC." also in stylized font. The wording appears to the right of the design of a stylized liposome.
Color is not claimed as a feature of the mark.
The English translation of AVANTI in the mark is GO FORWARD.
"POLAR LIPIDS, INC."

Trademark Events

Feb 2, 2024

Suspension Checked - To Attorney For Action

Jan 29, 2024

Teas Response To Suspension Inquiry Received

Dec 29, 2023

Suspension Checked - To Attorney For Action

Jun 2, 2023

Suspension Checked - To Attorney For Action

Nov 7, 2022

Report Completed Suspension Check Case Still Suspended

Aug 24, 2022

Applicant/Correspondence Changes (Non-Responsive) Entered

Aug 24, 2022

Teas Change Of Correspondence Received

Aug 24, 2022

Attorney/Dom.Rep.Revoked And/Or Appointed

Aug 24, 2022

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Aug 24, 2022

Teas Change Of Owner Address Received

Mar 21, 2022

Report Completed Suspension Check Case Still Suspended

Sep 20, 2021

Report Completed Suspension Check Case Still Suspended

Feb 25, 2021

Report Completed Suspension Check Case Still Suspended

Nov 4, 2020

Automatic Update Of Assignment Of Ownership

Jul 29, 2020

Notification Of Letter Of Suspension E-Mailed

Jul 29, 2020

Letter Of Suspension E-Mailed

Jul 29, 2020

Suspension Letter Written

Jul 8, 2020

Teas/Email Correspondence Entered

Jul 7, 2020

Correspondence Received In Law Office

Jul 7, 2020

Teas Response To Office Action Received

Jan 8, 2020

Notification Of Non-Final Action E-Mailed

Jan 8, 2020

Non-Final Action E-Mailed

Jan 8, 2020

Non-Final Action Written

Dec 30, 2019

Assigned To Examiner

Oct 3, 2019

Notice Of Design Search Code E-Mailed

Oct 2, 2019

New Application Office Supplied Data Entered

Sep 30, 2019

New Application Entered